Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ! ]$ T1 t! V9 ^* }: D+ C* s+ n; ] O
; l8 d9 K2 z- V+ }' f* {& A. H$ y
: F% ^, F+ G9 [7 R) J8 f
Sub-category:
2 g; F+ E% R* o0 j" ?2 PMolecular Targets
' `* S- y2 I, G, m- R V! V* ?
8 u8 w, p3 y$ q5 L Q; r3 |. }: t( b/ C- ]
Category:
6 W1 _: `0 l( i( X7 t- b2 dTumor Biology $ S% k1 ?- Y) P$ O
# H y& E3 t' }; M0 N" B& A
: W) b8 I/ d5 v$ D$ G
Meeting:- p! m8 j* x" q& H
2011 ASCO Annual Meeting
* k4 y9 W4 H* H4 X; y- n6 w: e* o" M, [, V" N
7 s/ I! u$ ~( V2 KSession Type and Session Title:2 d: W! U* L; b! ^* ^$ b2 N
Poster Discussion Session, Tumor Biology
( u9 x' P* `7 c) u2 F: t4 d# n$ K
5 l. J, d. q& n3 ^) L
# J& R1 C$ I9 y, M4 EAbstract No:
$ T5 V( r4 z \0 ]9 f6 E10517 8 T- S6 |5 n2 {/ ~) {, T
! O! K$ S, q: u- ^+ c
9 @ L! b8 ?! M8 f" F4 Z
Citation:2 \" Y4 H, l& l# k8 p {5 y: C
J Clin Oncol 29: 2011 (suppl; abstr 10517)
* u7 \9 E! M! I9 {" q! e, l" u7 @! m& r7 k3 M
# s+ J! c* D8 a a+ V: CAuthor(s):
& V/ d }+ H- b8 j( OJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " M0 M4 Y( t5 F* {" Y# M4 W# D
$ y" X( A/ }+ U
; R8 n0 ^% e& x
8 [; v! ~$ n8 b
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 P. r6 i4 o: O9 W z% L3 s+ e5 f& z3 d% g3 N/ [9 n. K
Abstract Disclosures3 _5 [" g9 e, S/ U! z0 j
5 C, g) R+ m5 C" F6 ?) f" g o& p
Abstract:6 o3 [* Y( A0 `3 Z: _3 D
# E3 @+ |) e8 h0 r: e6 [' X" |
; D8 D+ F3 v: L8 R3 ]4 E
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.6 p6 _- c" A: F1 p/ o1 J
. Q9 j& E/ ]- `- }) f
; Q P- V3 R# L% f1 w7 Y8 t |
11011102001537 )
. J+ O& y7 U2 N0 X9 H% c
显身卡
